Home » Stocks » Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc. (RARE)

Stock Price: $78.16 USD 0.56 (0.72%)
Updated Jul 31, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 4.67B
Revenue (ttm) 159.41M
Net Income (ttm) -300.51M
Shares Out 59.75M
EPS (ttm) -5.15
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 31, 2020
Last Price $78.16
Previous Close $77.60
Change ($) 0.56
Change (%) 0.72%
Day's Open 82.36
Day's Range 77.25 - 84.50
Day's Volume 333,138
52-Week Range 31.99 - 91.77

More Stats

Market Cap 4.67B
Enterprise Value 3.89B
Earnings Date (est) Nov 9, 2020
Ex-Dividend Date n/a
Shares Outstanding 59.75M
Float 56.96M
EPS (basic) -5.21
EPS (diluted) -5.15
FCF / Share -3.39
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 7.67M
Short Ratio 12.99
Short % of Float 18.55%
Beta 2.27
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 29.30
PB Ratio 7.67
Revenue 159.41M
Operating Income -395.87M
Net Income -300.51M
Free Cash Flow -203.06M
Net Cash 777.11M
Net Cash / Share 13.01
Gross Margin -164.76%
Operating Margin -248.33%
Profit Margin -188.50%
FCF Margin -127.38%
ROA -21.79%
ROE -39.66%
ROIC -54.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (19)

Buy 14
Overweight 1
Hold 4
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(8.69% upside)
Current: $78.16
Target: 84.95
*Average 12-month price target from 19 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth101.41%1871.48%1863.91%------
Gross Profit94.7150.352.610.13-----
Operating Income-424-371-329-248-148-56.78-32.28-15.99-6.56
Net Income-403-198-302-246-146-64.61-50.29-19.56-7.47
Shares Outstanding56.5849.7842.4539.5936.7828.763.381.381.62
Earnings Per Share-7.12-3.97-7.12-6.21-3.96-2.25-14.87-14.20-4.62
Operating Cash Flow-345-291-254-161-106-44.63-31.20-12.50-5.83
Capital Expenditures-24.83-4.08-2.79-10.19-4.96-2.15-0.41-1.09-0.55
Free Cash Flow-370-295-257-171-111-46.78-31.61-13.60-6.37
Cash & Equivalents75546023438443918853.8386.670.00
Total Debt29.76--------
Net Cash / Debt72546023438443918853.8386.670.00
Book Value654609383474531185-74.82-27.05-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Ultragenyx Pharmaceutical Inc.
Country United States
Employees 740
CEO Emil D. Kakkis

Stock Information

Ticker Symbol RARE
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: RARE
IPO Date January 31, 2014


Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia; and Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII. The company is also developing small-molecule pipeline comprising UX007, a synthetic triglyceride for the treatment of long chain fatty-acid oxidation disorders, which is a set of rare metabolic diseases that prevents the conversion of fat into energy; and gene therapy pipeline consisting of DTX301, an adeno-associated virus 8 gene therapy product candidate for the treatment of patients with ornithine transcarbamylase, as well as DTX401, an AAV8 gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia. In addition, the company is developing UX068, which is in preclinical development for the treatment of creatine transporter deficiency (CTD); and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Arcturus Therapeutics Holdings Inc. to develop additional nucleic acid therapies for rare diseases. Ultragenyx Pharmaceutical Inc. was founded in 2010 and is headquartered in Novato, California.